2009
DOI: 10.1038/jhg.2009.20
|View full text |Cite
|
Sign up to set email alerts
|

A pharmacogenetic study of CD4 recovery in response to HIV antiretroviral therapy in two South African population groups

Abstract: South Africa, like many other Southern African countries, has one of the highest HIV infection rates in the world and many individuals consequently receive antiretroviral therapy (ART). However, knowledge regarding (i) the prevalence of functional single nucleotide polymorphisms (SNPs) in pharmacologically relevant genes, and (ii) variance in pharmacotherapy both within and between different populations and ethnic groups is limited. The aim of this study was to determine whether selected polymorphisms in cytoc… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
27
1
2

Year Published

2011
2011
2021
2021

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 27 publications
(31 citation statements)
references
References 32 publications
1
27
1
2
Order By: Relevance
“…The cluster of differentiation 4 (CD4) cell count is more sensitive to sudden changes in a person's immunity and, thus, is a better indicator of HIV/AIDS progression2. CD4 counts can differ among individuals, depending on their age, sex and immune status.…”
Section: Introductionmentioning
confidence: 99%
“…The cluster of differentiation 4 (CD4) cell count is more sensitive to sudden changes in a person's immunity and, thus, is a better indicator of HIV/AIDS progression2. CD4 counts can differ among individuals, depending on their age, sex and immune status.…”
Section: Introductionmentioning
confidence: 99%
“…Effect of variants on immune response. When assessing the impact of polymorphisms on immune function using CD4 cell recovery as an indication of response to HAART, no significant association was found between the 516G4T and 785A4G SNPs and CD4 counts in South African Xhosa and Mixed-Ancestry HIV-positive patients (Parathyras et al, 2009). Similarly, no significant correlation was found between genotype and follow up viral loads following efavirenz treatment in a South African HIV-positive population (Gounden et al, 2010).…”
Section: Cyp2b6*6 (516g4t and 785a4g)mentioning
confidence: 86%
“…A total of 6.25% of individuals in the Xhosa population were found to be homozygous for the 516G4T SNP, as were 5.71% of the Cape mixed ancestry population (Parathyras et al, 2009). The 516G4T variant was reported at a frequency of 45, 31 and 37% in the Yoruba (Nigeria), Luhya (Kenya) and Maasai (Kenya) HapMap populations, respectively (Ikediobi et al, 2011).…”
Section: Cyp2b6*6 (516g4t and 785a4g)mentioning
confidence: 99%
See 1 more Smart Citation
“…[86][87][88][89][90][91][92][93][94][95][96] For example, the *1B allele of the CYP3A4 gene, which metabolises the majority of clinically available drugs, occurs at a much higher frequency in African individuals. 86,88,94 This may have profound implications for African individuals, as they remain underrepresented in pharmacogenetic and genomic research and a great deal of functional variation remains undocumented. 8 The CYP3A4 gene forms part of the cytochrome P450 (CYP) gene family, which encode a group of polymorphic Phase I drug metabolising enzymes that have formed the basis of a large number of pharmacogenetic candidate gene studies.…”
Section: Psychiatric Pharmacogenetics In South Africamentioning
confidence: 99%